Saroglitazar

Name: Saroglitazar in Primary biliary cholangitis: Definition and etiology
Published: 2026-09-14T15:39:06-04:00

Primary biliary cholangitis

Manufacturer: Zydus Therapeutics
Regulatory submission: NDA submitted by May 2026
Launch: Anticipated in April 2027, the start of Zydus fiscal year 2028
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Definition and etiology

1 evidence topic · 1 source

Etiologic uncertainty and autoimmune mechanisms

“Experts aren’t sure what causes primary biliary cholangitis.” (opens the source at this quote in a new tab)
“may trigger an autoimmune reaction” (opens the source at this quote in a new tab)